trifluorothymine deoxyriboside
trifluorothymine deoxyriboside Brand names, trifluorothymine deoxyriboside Analogs
trifluorothymine deoxyriboside Brand Names Mixture
- No information avaliable
trifluorothymine deoxyriboside Chemical_Formula
C41H42N4O8
trifluorothymine deoxyriboside RX_link
http://www.rxlist.com/cgi/generic2/verteporfin.htm
trifluorothymine deoxyriboside fda sheet
trifluorothymine deoxyriboside msds (material safety sheet)
trifluorothymine deoxyriboside Synthesis Reference
No information avaliable
trifluorothymine deoxyriboside Molecular Weight
718.794 g/mol
trifluorothymine deoxyriboside Melting Point
No information avaliable
trifluorothymine deoxyriboside H2O Solubility
No information avaliable
trifluorothymine deoxyriboside State
Solid
trifluorothymine deoxyriboside LogP
3.743
trifluorothymine deoxyriboside Dosage Forms
Powder for solution to be mixed for injection (2mg verteporfin/mL reconstituted verteporfin)
trifluorothymine deoxyriboside Indication
For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.
trifluorothymine deoxyriboside Pharmacology
Verteporfin, otherwise known as benzoporphyrin derivative, is a medication used in conjunction with laser treatment to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
trifluorothymine deoxyriboside Absorption
No information avaliable
trifluorothymine deoxyriboside side effects and Toxicity
Overdose of drug and/or light in the treated eye may result in nonperfusion of normal retinal vessels with the possibility of severe decrease in vision that could be permanent. An overdose of drug will also result in the prolongation of the period during which the patient remains photosensitive to bright light.
trifluorothymine deoxyriboside Patient Information
trifluorothymine deoxyriboside Organisms Affected
Humans and other mammals
